8-K: IDEAYA Biosciences Stockholders Affirm Board and Executive Compensation at 2025 Annual Meeting

IDEAYA Biosciences, Inc. announced the successful approval of all three proposals at its 2025 Annual Meeting of Stockholders, including the re-election of two Class III directors, the ratification of its independent auditor, and the advisory approval of executive compensation.

Summary

• IDEAYA Biosciences, Inc. held its 2025 Annual Meeting of Stockholders on June 24, 2025.
• As of the record date, April 28, 2025, 87,577,550 shares of common stock were outstanding and entitled to vote.
• Stockholders re-elected Jeffrey L. Stein, Ph.D. to the Board of Directors with 69,077,770 votes For and 7,955,948 votes Withheld.
• Stockholders re-elected Scott W. Morrison to the Board of Directors with 42,132,938 votes For and 34,900,780 votes Withheld.
• The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified with 79,645,454 votes For, 228,609 votes Against, and 190,397 Abstentions.
• The non-binding, advisory vote to approve the compensation of the Company's named executive officers passed with 59,798,805 votes For, 17,040,207 votes Against, and 194,706 Abstentions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While all proposals passed as expected, the significant 'Withheld' votes for one director and 'Against' votes for executive compensation indicate underlying shareholder dissent, preventing a purely positive assessment.

Positives

• All three proposals presented at the Annual Meeting were approved by stockholders, indicating general support for the company's governance and operational plans.
• The ratification of PricewaterhouseCoopers LLP as the independent auditor received overwhelming support, with 99.4% of votes cast in favor, demonstrating strong confidence in the company's financial oversight.

Negatives

• Scott W. Morrison's re-election as a Class III director received a significant number of 'Withheld' votes (34,900,780), representing approximately 45.3% of the votes cast (excluding broker non-votes), suggesting notable shareholder dissent regarding his re-appointment.
• The non-binding advisory vote on executive compensation, while approved, saw a substantial number of 'Against' votes (17,040,207), accounting for approximately 22.2% of the votes cast (excluding broker non-votes), indicating some shareholder dissatisfaction with current executive pay practices.

Future Outlook

The document does not contain specific forward-looking statements or guidance beyond the outcomes of the stockholder votes.

Management Comments

• The report was signed by Yujiro Hata, President and Chief Executive Officer of IDEAYA Biosciences, Inc.

Industry Context

This 8-K filing details routine corporate governance matters for a publicly traded biotechnology company. The outcomes of the votes on director elections, auditor ratification, and executive compensation are standard agenda items for annual stockholder meetings across industries. The level of dissent on certain proposals, while not preventing their passage, may warrant attention from a corporate governance perspective, aligning with broader trends of increased shareholder scrutiny on board independence and executive pay.

Comparison to Industry Standards

• The overall approval of all proposals is generally in line with typical outcomes for annual stockholder meetings in the biotechnology sector, where management-backed proposals usually pass.
• The significant percentage of 'Withheld' votes for Scott W. Morrison's re-election (approximately 45.3% of votes cast, excluding broker non-votes) is higher than the average dissent typically observed for uncontested director elections in the industry, which often see 'For' votes well above 90%. This suggests a notable segment of shareholders expressed dissatisfaction.
• The 22.2% 'Against' vote for the advisory executive compensation proposal, while passing, is also higher than the average for similar proposals in the industry, where 'Say-on-Pay' votes often pass with over 80-90% approval. This indicates a more pronounced level of shareholder concern regarding compensation practices compared to many peers.

Stakeholder Impact

• Shareholders: Approved the re-election of directors and executive compensation, but a notable portion expressed dissent on specific proposals, indicating areas for potential future engagement or review by the board.
• Management: Received approval for their proposed slate of directors and executive compensation, though the level of dissent on the latter may prompt a review of compensation strategies.

Next Steps

• The re-elected Class III directors, Jeffrey L. Stein, Ph.D. and Scott W. Morrison, will hold office until the 2028 annual meeting of stockholders or until their respective successors are elected.

Key Dates

Recommendation

Keywords

IDEAYA Biosciences, IDYA, Annual Meeting, Stockholder Vote, Corporate Governance, Director Election, Executive Compensation, Auditor Ratification, SEC Filing, 8-K